The respiratory system is continuously exposed to airborne particles containing lipopolysaccharide. Our laboratory established previously that the hydrophobic surfactant protein C (SP-C) binds to LPS and to one of its cellular receptors, CD14. Here we examined the influence of SP-C, and of a synthetic analog, on some cellular in-vitro effects of lipopolysaccharide. When associated to vesicles of dipalmitoylphosphatidylcholine, SP-C inhibits the binding of a tritium-labeled lipopolysaccharide to the macrophage cell line RAW 264.7. In similar conditions of presentation, SP-C inhibits the mitogenic effect of lipopolysaccharide on mouse splenocytes, and inhibits the lipopolysaccharide-induced production of tumor necrosis factor-α by peritoneal and alveolar macrophages, and of nitric oxide by RAW 264.7 cells. In contrast, tumor necrosis factor-α production induced by a lipopeptide, and nitric oxide production induced by picolinic acid, were not affected by SP-C.
INTRODUCTION

Bacterial lipopolysaccharide (LPS) is a component of the Gram-negative bacterial cell wall
that is released in vivo into the circulation during infection and sepsis. A common clinical complication of sepsis is lung injury, with frequent development of an acute respiratory distress syndrome (1) . LPS may also be shed from the outer bacterial membrane into the environment, where it is ubiquitously present. Airborne LPS has been detected in several occupational environments associated with conditions such as swine worker's disease (2) , cotton dust worker's disease (3), farmer's disease (4) , and lung disease in the fiberglass industry (5) . The presence of LPS in house dust (6, 7) , and its possible role in domestic asthma (8, 9) have also been reported. Due to inhalation of airborne particles containing bacteria and LPS, the respiratory system is continuously exposed to this potent proinflammatory compound. In n ormal subjects, acute inhalation of LPS induces systemic (10) and airway inflammation (11) , in the absence of significant change in lung function (12) . 4 surfactant proteins SP-B and SP-C, they are consid ered to be critical for the absorption and spreading of the surfactant film at the air/liquid interface, but their possible role in lung defense remains elusive. We established however in previous studies that SP-C, but not SP-B, can bind to the lipid A region of LPSs of various phenotypes (16, 17) . We also found recently (18) that SP-C interacts with CD14, a co-receptor for LPS expressed by macrophages and other cell types (19) . The aim of this study was to determine if these molecular interactions influence the responses of immunocompetent cells to LPS. 6 mixtures (sterilized under U.V. light) of purified surfactant components (2 µg) and DPPC (18 µg) were sonicated in 1 ml of CM, and 100 µl of the vesicles obtained were added to the cells in a final volume of 250 µl. It has been established that the vesicles obtained by this technique are multilamellar, and heterogeneous in size (80-500 nm), with a phase transition of 40.1 °C (26) . The phospholipids/protein ratio of these vesicles (90/10 by weight) is similar to that of natural surfactant, and our previous stud y (16) indicated that their apparent density on a salt gradient is also similar to natural surfactant. The binding of tritium-labeled LPS to SP-C was analyzed as described previously (16) , with lipid vesicles loaded with SP-C and containing BSA (added to reduce nonspecific binding). It has been shown (27) that the presence of BSA in the vesicles has little impact on their size and density.
Peroxynitrite was synthesized from reaction of gaseous nitric oxide with hydrogen peroxide as described previously (28) . Concentration in peroxynitrite was measured using the molar extinction coefficient of 1670 M -1 cm -1 at 302 nm.
The mouse monocyte-macrophage cell line RAW 264.7 (ECACC catalog number 910062702) was maintained as an adherent culture in CM supplemented with 10% heatinactivated and endotoxin-free FCS.
Alveolar and peritoneal macrophages were collected from normal, uninfected Swiss outbred mice (six to twelve weeks of age). Alveolar macrophages were harvested from the mouse lungs by bronchoalveolar lavage. Peritoneal exudates were harvested five days after i.p. injection of 1.7 ml of thioglycollate broth. Alveolar and peritoneal cells were centrifuged, re-suspended in CM, and immediately plated in plastic plates of 24 wells. After three hours at 37° C in a 5% CO 2 atmosphere, non-adherent cells were removed by two to three washings with RPMI-1640.
Cellular assays
The binding of tritium-labeled LPS to macrophages was analyzed as described previously (29) . TNF-α present in culture supernatant s at 24 hours after stimulation was measured by specific sandwich enzyme-linked immunosorbent assay (ELISA) according to the manufacturer's instructions (eBioscience, San Diego, CA). Nitric oxide production was estimated by measuring the nitrite concentration of the cell supernatants by the Griess reaction (30) 
RESULTS
Inhibition of LPS-binding to RAW cells, and LPS-induced production of TNF-α
We demonstrated in previous studies that native SP-C from human or animal origin, and several synthetic analogs of these molecules, interact with the lipid A moiety of LPSs (17) .
Because macrophages play a central role in the pathophysiological effects of LPS, we analyzed the influence of SP-C on the binding of LPS to this cell type, and on the resulting cellular effects. We first used the mouse monocyte-macrophage cell line RAW 264.7, which is considered as a good model of LPS-binding and LPS response (31, 32) . In an initial experiment, we examined the influence of different SP-C peptides on the production of TNF-α induced by LPS in this cell line. We compared porcine SP-C, mouse SP-C, and SP-C(LKS), which is a non-palmitoylated synthetic analog of SP-C. The structures of these molecules are represented in Figure 1 . Because SP-C and its synthetic analogs are hydrophobic and almost insoluble in aqueous culture media, these peptides were incorporated into vesicles of DPPC as described previously (16) . show that a marked inhibition of LPS-induced production of TNF-α was observed in the presence of vesicles containing porcine or mouse SP-C, or SP-C(LKS) (94, 55, and 67 % inhibition, respectively), as compared to the response induced in the presence of void vesicles.
Because the effect of mouse SP-C was not significantly different from that of SP-C(LKS), we used the latter in all further experiments. The influence of SP-C(LKS) (400 pmoles/ml) on the production of TNF-α induced by different LPSs (40 ng/ml) in RAW cells was also examined.
We found that there was no statistically significant differences between the inhibitory effects of SP-C(LKS) on the T NF-α production induced by five different LPSs, including the smooth-type LPS from K. pneumoniae, and four rough-type LPSs from Salmonella and E.
coli (data not shown).
The inhibition of cytokine production in the presence of SP-C can be either due to a vesicles induced a marked inhibition of LPS binding, whereas no effect was observed with a suspension of the synthetic peptide. This is likely due to the fact that SP-C, which is highly hydrophobic, leads to aggregates in aqueous media, in which the LPS-binding site of the peptide is much less accessible. We also observed that the presence of serum in the binding medium did not influence these results. In a second experiment ( Figure 3B ),do not require serum, we used these conditions in all further experiments.
Inhibition of LPS-induced production of TNF-α in alveolar and peritoneal macrophages
To ensure that the results described above are not restricted to the cell line used, we analyzed 
LPS). At lower SP-C(LKS):LPS ratios (LPS concentrations higher than 50
ng/ml), the ability of SP-C(LKS) to neutralize the LPS effect decreased progressively.
To ensure that the inhibitory effect of SP-C(LKS) is not due to some general inhibition of TNF-α synthesis, we used as a TNF-α inducer a lipopeptide structurally unrelated to LPS: the mitogenic tripalmitoyl pentapeptide (MTPP). We found ( Figure 5B ) that at 100 ng/ml, this agent induced a low but highly significant production of TNF-α. However, unlike that of LPS, this effect was not inhibited in the presence of SP-C(LKS). Therefore, this result shows that SP-C(LKS) does not block the ability of macrophages to produce TNF-α.
Inhibition of LPS-induced production of nitric oxide in RAW cells
Another important response involved in the antimicrobial activities of macrophages is the production of nitric oxide. Macrophage nitric oxide s ynthase is the product of a transcriptionally inducible (iNOS) gene, whose maximal expression requires IFN-γ plus a second stimulus (35) . Particularly, the RAW 264.7 monocyte-macrophage cell line can be efficiently activated by LPS and IFN-γ to produce NO (35, 36) . We thus analyzed the capacity To check the specificity of this inhibitory effect, we used picolinic acid, an end catabolite of L-tryptophan which has been reported to act as a costimulus with IFN-γ for the induction of NO production (37) . We confirmed that picolinic acid stimulates NO production in RAW cells. However, SP-C(LKS) did not reduce significantly this effect, even when used at relatively high concentrations (800 pmoles per well) ( Figure 7B ). Therefore, SP-C(LKS) does not block the activation of the iNOS gene, and suggests that as for TNF-α, the inhibition of LPS-induced NO production by SP-C(LKS) is likely due to a direct neutralization of LPS.
Peroxynitrite does not influence the interaction between LPS and SP-C
Nitric oxide produced by macrophages can react with superoxide anion produced by the same cells, to form peroxynitrite, a strong oxidant which causes lipid peroxidation ( 38) , and oxidation of specific amino acid residues of proteins such as cysteine, methionine, tyrosine, and tryptophan (39) . It has been shown that peroxynitrite is produced in the lung during acute endotoxemia (40) . Therefore, it was conceivable that peroxynitrite could oxidize SP-C, and thus destroy its capacity to interact with LPS, which would lead to an amplification of the endotoxin effects. The peptide SP-C/BR (see structure in Figure 1 ) is appropriate for testing this putative damaging mechanism because this synthetic analog of SP-C binds efficiently to LPS (17) , and because it contains four possible oxidation sites: 2 cysteine residues in its hydrophilic N-terminal region (residues 5 and 6), and two tyrosine residues in its hydrophobic C-terminal region (residues 28 and 35). This peptide, and mouse SP-C were exposed to peroxynitrite under conditions used previously (28) It was therefore necessary to determine which of these upregulating or downregulating effects was promoted by SP-C. For this purpose we used a rough-type LPS to ensure that the observed effect is mediated by lipid A, the biologically active region of endotoxin, and also because several bacteria infecting the air ways (Hemophilus influenzae, Bordetella pertussis,
Neisseria meningitidis) have LPSs with short carbohydrate chains (lipooligosaccharides:
LOS) ( 48-50). We first examined the influence of SP-C on the binding of LPS to a macrophage cell line. SP-C in lipid vesicles clearly inhibited the binding, but was considerably less active in suspension without lipids (Fig.3) . This is understandable inasmuch as SP-C is probably the most hydrophobic protein yet encountered in mammals, and can form A specific molecule has not necessarily the same effect on all cellular responses to LPS. For example, LBP, which enhances in macrophages the production of TNF-α (44), has no influence on the production of nitric oxide by this cell type (53) . We thus analyzed the effect of SP-C on NO production in RAW 264.7 cells, and found that this LPS-induced production is also blocked by SP-C. This inhibition of NO production may be of critical importance because it should lead to an inhibition of peroxynitrite, which is formed by reaction of NO with superoxide anions, and plays a major role in acute lung injury and acute respiratory distress syndrome (54) . If a degradation of the LPS-binding site of SP-C by this very reactive agent had been possible, it would lead to a loop of sustained or auto-amplified inflammation. This is apparently not the case, and we found that the LPS-binding site of SP-C seems insensitive to peroxynitrite, unlike the activity of whole surfactant and SP-A, reported to be damaged by peroxynitrite (55, 56) .
The inhibitory activity of SP-C on macrophage responses to LPS can be either due to its capacity to neutralize LPS, or to interfere with a biochemical event of the signaling cascade leading to the activation of the TNF-α and iNOS genes. The latter possibility can be excluded since we found that SP-C has no influence on the levels of TNF-α induced by MTPP, and on the production of NO triggered by picolinic acid. Therefore, it seems reasonable to suppose that SP-C acts by direct and specific neutralization of LPS, and this hypothesis is supported by the observation that SP-C blocks also the mitogenic effect of LPS on splenocytes, and the binding of LPS to RAW 264.7 cells.
We established recently that SP-C binds also to CD14, and enhances the binding of LPS to CD14 in solution or expressed by granulocytes (18) . However, in the present study, we found that SP-C did not enhance but rather inhibited the binding of LPS to RAW 264.7 cells, although these cells express normal levels of membrane CD14. This discrepancy probably reflects the fact that in macrophages other membrane constituents such as scavenger receptors, TLR4, and CD11/CD18 may contribute much more than CD14 to LPS binding (57, 58) .
The inhibiting effect observed in this study indicates that the surfactant component SP-C plays probably a major role in lung defense mechanisms by trapping LPS and preventing it to trigger its inflammatory effect on alveolar cells. The efficiency of SP-C, as compared to other surfactant components, could be due in part to its high abundance (65% of the surfactant proteins on a molar basis), and in part to the high resistance of its LPS-binding site to degradation by peroxynitrite. When artificially introduced in vivo in another tissue than the lungs, the LPS-neutralizing activity of SP-C can be blunted by the presence of other constituents. This is particularly the case of the blood circulation, where the synthetic analog of SP-C cannot block LPS-induced production of TNF-α in vivo. This is likely due to a wellknown phenomenon: the redistribution of lipids and hydrophobic molecules in the circulation (59, 60) . SP-C, as other hydrophobic drugs, can be redistributed from liposome vesicles to circulating lipoproteins, or to "lipid transfer protein" (LTP), and thus become unavailable for neutralization of LPS. Lipoproteins and LTP, which are abundant in the blood, are no rmally not present in the alveolar space, and this may allow lung SP-C to interact with LPS under physiological conditions. Further investigations are required to confirm this hypothesis. 
